Documents

Filter documents

pdf icon

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

File size: 327kb | Date: 15 January 2020 | Clinical Statements - PDF

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

pdf icon

Promoting Scotland’s sexual and reproductive health: A joint manifesto

File size: 232kb | Date: 1 March 2021 | FSRH Policy and External Affairs - PDF

Joint manifesto by the Faculty of Sexual and Reproductive Healthcare (FSRH), the Royal College of Obstetricians and Gynaecologists (RCOG) and the British Association for Sexual Health (BASHH) ahead of the 2021 elections in Scotland

pdf icon

FSRH Response to the Department of Health and Social Care consultation on the home use of both pills for early medical abortion up to 10 weeks gestation in England

File size: 268kb | Date: 26 February 2021 | FSRH Consultation Response - PDF

The Department of Health and Social Care is consulting on whether to continue to allow home use of mifepristone and misoprostol for early medical abortion (EMA) up to 10 weeks gestation after the pandemic. In our consultation response, we make the case for making this measure permanent in England.

pdf icon

FSRH response to Welsh Government’s consultation on the home use of abortion pills

File size: 246kb | Date: 23 February 2021 | FSRH Consultation Response - PDF

The Welsh Government is consulting on whether to continue to allow home use of mifepristone and misoprostol for early medical abortion (EMA) up to 10 weeks gestation after the pandemic. In our consultation response, we make the case for making this measure permanent in Wales.

pdf icon

Members evidence request service sample response

File size: 127kb | Date: 18 February 2021 | Clinical Effectiveness Unit - PDF

Read a sample question and answer from our FSRH Clinical Effectiveness Unit (CEU) member evidence request service.

pdf icon

FSRH CEU response public consult desogestrel POP as pharmacy medicine - Feb 2021

File size: 380kb | Date: 18 February 2021 | FSRH Response - PDF

This statement is a FSRH CEU response to a public consultation conducted by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding licensing of two brands of desogestrel 75mcg progestogen-only pill (POP) as Pharmacy Medicines (P). The products are Hana® (Laboratoire HRA Pharma) and Lovima® (Maxwellia Ltd).

pdf icon

FSRH Clinical Guideline: Progestogen-only Implant (February 2021)

File size: 802kb | Date: 16 February 2021 | Current Clinical Guidance - PDF

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only implants currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.